FY2026 Earnings Estimate for VRTX Issued By Erste Group Bank

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Stock analysts at Erste Group Bank lowered their FY2026 earnings per share estimates for Vertex Pharmaceuticals in a research note issued to investors on Monday, April 27th. Erste Group Bank analyst H. Engel now expects that the pharmaceutical company will earn $16.82 per share for the year, down from their prior forecast of $16.90. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $16.74 per share. Erste Group Bank also issued estimates for Vertex Pharmaceuticals’ FY2027 earnings at $19.56 EPS.

A number of other equities analysts have also recently weighed in on the company. Barclays upped their price target on Vertex Pharmaceuticals from $606.00 to $607.00 and gave the stock an “overweight” rating in a report on Tuesday, February 17th. Wolfe Research raised Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 price target for the company in a report on Tuesday, January 6th. Morgan Stanley upped their price target on Vertex Pharmaceuticals from $596.00 to $612.00 and gave the stock an “overweight” rating in a report on Friday, April 10th. Oppenheimer upped their price target on Vertex Pharmaceuticals from $540.00 to $600.00 and gave the stock an “outperform” rating in a report on Tuesday, March 10th. Finally, Weiss Ratings cut Vertex Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $555.00.

Vertex Pharmaceuticals Trading Up 1.0%

NASDAQ VRTX opened at $430.14 on Wednesday. The stock has a market capitalization of $109.41 billion, a price-to-earnings ratio of 28.06, a PEG ratio of 1.90 and a beta of 0.36. Vertex Pharmaceuticals has a twelve month low of $362.50 and a twelve month high of $510.77. The stock has a 50-day moving average of $455.60 and a 200 day moving average of $449.26.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The company had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.18 billion. During the same quarter in the previous year, the company earned $3.98 EPS. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Mark E. Bunnage sold 2,021 shares of the company’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total value of $930,529.03. Following the completion of the sale, the executive vice president directly owned 12,914 shares in the company, valued at $5,945,993.02. This represents a 13.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Carmen Bozic sold 2,329 shares of Vertex Pharmaceuticals stock in a transaction on Friday, March 13th. The stock was sold at an average price of $481.79, for a total value of $1,122,088.91. Following the transaction, the chief marketing officer owned 35,405 shares in the company, valued at approximately $17,057,774.95. This represents a 6.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 80,431 shares of company stock valued at $37,875,167 in the last three months. Company insiders own 0.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Motiv8 Investments LLC acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at $26,000. Swiss RE Ltd. acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth about $28,000. Eagle Bay Advisors LLC purchased a new stake in Vertex Pharmaceuticals in the 4th quarter valued at about $29,000. IMG Wealth Management Inc. raised its holdings in Vertex Pharmaceuticals by 277.8% in the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock valued at $31,000 after buying an additional 50 shares during the period. Finally, Colonial Trust Co SC raised its holdings in Vertex Pharmaceuticals by 118.8% in the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 38 shares during the period. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Broker upgrade: Truist upgraded Vertex to a “strong-buy,” which can attract buying interest and supports near-term bullishness. Zacks Truist Upgrade
• Positive Sentiment: Product tailwinds ahead of Q1: Analysts highlight continued Trikafta demand and rising sales of Alyftrek, plus growing contributions from cell/gene therapies Casgevy and Journavx — these revenue drivers are the main reasons investors expect solid top-line growth. Vertex Gears Up to Report Q1 Earnings
• Neutral Sentiment: Valuation re-rate conversation: Recent share weakness has prompted fresh valuation analysis and debate over whether current multiples fairly reflect Vertex’s growth outlook — this is creating mixed positioning among funds and analysts. Vertex Valuation Overview
• Negative Sentiment: Major investor trimming exposure: Conestoga Capital Advisors disclosed exit from Vertex, citing valuation that no longer offers an attractive risk-reward — such institutional selling can pressure the stock. Conestoga Capital Exit
• Negative Sentiment: Analyst caution on earnings beat: Several previews note Vertex may not have the “right combination” for an earnings beat despite expected EPS growth, which raises the risk of a muted or negative reaction if results merely meet consensus. Earnings Preview / Caution

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.